open access
Chronic pain evaluation in breast cancer patients using the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS): a single centre cross-sectional retrospective study
, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11, 3
Affiliations- Department of Radiation Oncology, JLN Medical College and Hospital, Ajmer, India
- Department of General Surgery, RUHS College of Medical Sciences, Jaipur, India
- School of Applied Science, Suresh Gyan Vihar University, Jagatpura, Jaipur, India
- Department of Laboratory, All India Institute of Medical Sciences, New Delhi, India
- Department of Hematology and Medical Oncology, Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine, Mount Sinai, New York, United States
- Department of Dentistry, GMERS Medical College, Gandhinagar, Gujarat, India
- Department of Materials and Manufacturing School of Engineering University of Wolverhampton England, United Kingdom
- Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, United States
- Department of Ophthalmology, Washington University School of Medicine, St Louis, Missouri, United States
- Department of Medicine, NYU Grossman School of Medicine, New York, United States
- Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, New York, United States
open access
Abstract
Background: Breast cancer is the most common cancer in India, and the number of survivors has increased over the last few years. Pain is one of the most common symptoms during cancer treatment due to either the disease itself or the adverse effects of treatment. The available data suggests that breast cancer patients have a high prevalence of neuropathic pain.
Patients and methods: A cross-sectional observational study was done at the Department of Radiation Oncology, between November 2021 to June 2022. The patients were admitted and screened for participation, non-metastatic post-operative breast cancer on regular follow-up for 2 years after their last chemotherapy or radiotherapy and not having any chronic neuropathy disease and the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) pain scale was used to assess the neuropathy pain status of patients. Patients’ demographics, clinical characteristics, and treatment of surgery, radiation therapy, and chemotherapy were collected and the comparison of the pain scores between the patients was analysed.
Results: A total of 149 patients were included in the study. S-LANSS score was calculated in the study population and more than 61% of participants reported a score equal to or greater than 12, suggesting a predominant neuropathic pain component. Autonomic dysfunction, thermal pain, and allodynia were more prevalent in patients who underwent mastectomies compared to breast-conserving surgery. Whereas the dysesthesia and autonomic dysfunction score was higher in only the anthracycline group.
Conclusions: The most important index for quality of life in cancer patients is the presence of persistent chronic pain and it is important to classify it accordingly in order to provide the best management. Using the S-LANSS score, the pattern of neuropathic pain can be determined early which leads to early intervention.
Abstract
Background: Breast cancer is the most common cancer in India, and the number of survivors has increased over the last few years. Pain is one of the most common symptoms during cancer treatment due to either the disease itself or the adverse effects of treatment. The available data suggests that breast cancer patients have a high prevalence of neuropathic pain.
Patients and methods: A cross-sectional observational study was done at the Department of Radiation Oncology, between November 2021 to June 2022. The patients were admitted and screened for participation, non-metastatic post-operative breast cancer on regular follow-up for 2 years after their last chemotherapy or radiotherapy and not having any chronic neuropathy disease and the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) pain scale was used to assess the neuropathy pain status of patients. Patients’ demographics, clinical characteristics, and treatment of surgery, radiation therapy, and chemotherapy were collected and the comparison of the pain scores between the patients was analysed.
Results: A total of 149 patients were included in the study. S-LANSS score was calculated in the study population and more than 61% of participants reported a score equal to or greater than 12, suggesting a predominant neuropathic pain component. Autonomic dysfunction, thermal pain, and allodynia were more prevalent in patients who underwent mastectomies compared to breast-conserving surgery. Whereas the dysesthesia and autonomic dysfunction score was higher in only the anthracycline group.
Conclusions: The most important index for quality of life in cancer patients is the presence of persistent chronic pain and it is important to classify it accordingly in order to provide the best management. Using the S-LANSS score, the pattern of neuropathic pain can be determined early which leads to early intervention.
Keywords
neuropathic pain, S-LANSS, chronic pain, breast cancer, pain measurement
Supp./Additional Files (1)
About this articleTitle
Chronic pain evaluation in breast cancer patients using the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS): a single centre cross-sectional retrospective study
Journal
Palliative Medicine in Practice
Issue
Article type
Research paper
Pages
4-10
Published online
2023-07-13
Page views
484
Article views/downloads
316
DOI
Bibliographic record
Palliat Med Pract 2024;18(1):4-10.
Keywords
neuropathic pain
S-LANSS
chronic pain
breast cancer
pain measurement
Authors
Dhiraj Daga
Narender Singh Shah
Sanchit Jain
Gaurav Sharma
Harsh Goel
Sooyun Caroline Tavolacci
Boski Gupta
Kiran Gulia
Tabish H Khan
Darksha Usmani
Akash Gujral
Naoshad Muhammad
Sandeep Mittan
Poonam Banthia
References (20)- IARC Inc. India Fact Sheet 2020. Globocan. 2020; 361: 2.
- Satija A, Joad AK, Rana SP, et al. The burden of cancer-related neuropathic pain: a multi-centric cross-sectional observational study from north india. Indian J Palliat Care. 2021; 27(1): 104–108.
- Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008; 70(18): 1630–1635.
- Satija A, Ahmed SM, Gupta R, et al. Breast cancer pain management - a review of current & novel therapies. Indian J Med Res. 2014; 139(2): 216–225.
- Yoon SoY, Oh J. Neuropathic cancer pain: prevalence, pathophysiology, and management. Korean J Intern Med. 2018; 33(6): 1058–1069.
- Bennett MI, Rayment C, Hjermstad M, et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012; 153(2): 359–365.
- Bhatnagar S, Mishra S, Roshni S, et al. Neuropathic pain in cancer patients--prevalence and management in a tertiary care anesthesia-run referral clinic based in urban India. J Palliat Med. 2010; 13(7): 819–824.
- Ilhan E, Chee E, Hush J, et al. The prevalence of neuropathic pain is high after treatment for breast cancer: a systematic review. Pain. 2017; 158(11): 2082–2091.
- Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997; 48(2): 332–338.
- Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001; 92(1-2): 147–157.
- Bennett MI, Smith BH, Torrance N, et al. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005; 6(3): 149–158.
- Reyes-Gibby C, Morrow PK, Bennett MI, et al. Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool. J Pain Symptom Manage. 2010; 39(5): 882–889.
- Couceiro T, Lima L, Júnior MC, et al. Prevalence of neuropathic pain in patients with cancer. Brazilian J Pain. 2018; 1(3).
- Koc R, Erdemoglu AK. Validity and reliability of the Turkish self-administered leeds assessment of neuropathic symptoms and signs (S-LANSS) questionnaire. Pain Med. 2010; 11(7): 1107–1114.
- Chopra B, Kaur V, Singh K, et al. Age shift: Breast cancer is occurring in younger age groups - Is it true? Clin Cancer Investig J. 2014; 3(6): 526.
- Mohite R. Socio-demographic and clinical profile of women with breast cancer. Int J Heal Sci Res. 2015; 5: 44–8.
- Sathwara JA, Balasubramaniam G, Bobdey SC, et al. Sociodemographic factors and late-stage diagnosis of breast cancer in India: a hospital-based study. Indian J Med Paediatr Oncol. 2017; 38(3): 277–281.
- Leysen L, Beckwée D, Nijs Jo, et al. Risk factors of pain in breast cancer survivors: a systematic review and meta-analysis. Support Care Cancer. 2017; 25(12): 3607–3643.
- Baek SK, Shin SW, Koh SJ, et al. Significance of descriptive symptoms and signs and clinical parameters as predictors of neuropathic cancer pain. PLoS One. 2021; 16(8): e0252781.
- Mejdahl MK, Christoffersens KB, Andersen KG. Development and validation of a screening tool for surgery-specific neuropathic pain: neuropathic pain scale for postsurgical patients. Pain Physician. 2019; 22(2): E81–E90.
